Sponsors › University Medical Centre Ljubljana
University Medical Centre Ljubljana
Every GLP‑1 and incretin trial, approval and scheduled result we hold for University Medical Centre Ljubljana, drawn from ClinicalTrials.gov and Drugs@FDA.
University Medical Centre Ljubljana is an academic or hospital sponsor, not a drug company with 13 trials in the incretin class on file here, across 3 molecules. The programme is split between 1 early-stage trial and 12 in phase 3 or later. The next scheduled result is 2027-06-30.
- Molecules
- liraglutide · semaglutide · tirzepatide
- Trials on file
- 13
- Active trials
- 2
- Results scheduled
- 0
- Approved FDA submissions
- 0
Trials on file
All 13 incretin trials recorded for this sponsor, active first.